ClinicalTrials.gg
RecruitingNCT07686029ERAS-MALTOUpdated Jul 6, 2026

Use of Maltodextrins in the ERAS Preoperative Fasting Protocol in Pediatric Surgery

An interventional study of Maltodextrin Clear Liquid and Non-Sugared Clear Liquid in Preoperative Care, Anxiety and Pediatric Surgery, sponsored by Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria. Recruiting at 1 site in Italy. Open to participants aged 3 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Primary conditionFastingRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fasting
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's title name Fasting.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2025, registered Jun 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Study summary

This monocentric prospective randomized controlled pilot study aims to evaluate the effectiveness of preoperative maltodextrin administration within an Enhanced Recovery After Surgery (ERAS) protocol in pediatric surgical patients. Children aged 3 to 8 years undergoing elective day surgery will be randomized 1:1 to receive either a maltodextrin-containing clear liquid or a non-sugared clear liquid before surgery. The study will assess preoperative anxiety, patient compliance, parental anxiety, oxidative stress markers, postoperative feeding tolerance, and postoperative recovery outcomes.

Read the detailed description

Enhanced Recovery After Surgery (ERAS) protocols are multidisciplinary perioperative care programs developed to reduce surgical stress, improve postoperative recovery, and shorten hospital stay. In adult surgical populations, preoperative administration of carbohydrate-rich clear fluids has been associated with reduced insulin resistance, improved metabolic response, reduced postoperative nausea, and improved patient comfort.

Evidence regarding the use of these strategies in pediatric surgical patients remains limited. This prospective randomized controlled no-profit pilot study aims to evaluate the clinical impact of preoperative maltodextrin administration in children undergoing elective surgery.

Approximately 200 pediatric patients aged 3 to 8 years undergoing elective day surgery at the Pediatric Surgery Unit of the Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo of Alessandria will be enrolled. Participants will be randomized 1:1 to receive either a maltodextrin-containing clear liquid or a non-sugared clear liquid two hours before surgery.

Primary outcome evaluation includes preoperative anxiety assessed using the Modified Yale Preoperative Anxiety Scale (m-YPAS). Secondary outcomes include parental anxiety, oxidative stress markers, postoperative feeding tolerance, postoperative vomiting, postoperative pain evaluation, and discharge eligibility after surgery.

Clinical, demographic, laboratory, anesthesiologic, and perioperative data will be collected and analyzed to assess the feasibility and effectiveness of this ERAS-based intervention in pediatric surgical patients.

02

Conditions studied

  • Preoperative Care
  • Anxiety
  • Pediatric Surgery

Browse trials for

Keywords

  • Enhanced Recovery After Surgery
  • ERAS
  • Maltodextrins
  • Preoperative Anxiety
  • Pediatric Surgery
  • Day Surgery
  • Carbohydrate Loading
  • Fasting
  • Randomized Controlled Trial
  • Modified Yale Preoperative Anxiety Scale
  • Postoperative Recovery
  • Insulin Resistance
03

In context

Fasting Reclassified

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

This study's planned enrollment of 200 is above the median of 45 across 311 interventional studies indexed under Fasting.

Browse Fasting studies →

Lead sponsor

Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria is the lead sponsor of 37 studies on the registry; 13 are open to participants now.

Compared within Fasting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients aged 3 to 17 years
  • Patients undergoing elective surgery in a day surgery setting
  • Surgical procedure duration less than 60 minutes
  • Written signed by a parent or legal guardian

Exclusion criteria

Exclusion Criteria:

  • Maltodextrin intake within 3 hours before surgery
  • Allergy or intolerance to maltodextrins
  • Diabetes mellitus or other metabolic disorders potentially affecting study variables
  • Inadequate nutritional status based on (BMI)
  • Absence of signed by parent or legal guardian
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Maltodextrin Group

    Pediatric patients receiving 125 mL of a clear liquid containing maltodextrins two hours before elective surgery as part of the ERAS preoperative fasting protocol.

    Dietary Supplement: Maltodextrin Clear Liquid

  • Placebo comparator
    Control Group

    Pediatric patients receiving 125 mL of a non-sugared clear liquid (water, tea, or chamomile) two hours before elective surgery.

    Other: Non-Sugared Clear Liquid

Interventions

  • Dietary supplementMaltodextrin Clear Liquid

    Administration of 125 mL of a clear liquid containing maltodextrins two hours before elective pediatric surgery as part of the ERAS preoperative fasting protocol.

    Also known as: Carbohydrate Loading, Maltodextrins

  • OtherNon-Sugared Clear Liquid

    Administration of 125 mL of a non-sugared clear liquid (water, tea, or chamomile) two hours before elective pediatric surgery.

    Also known as: Placebo Beverage, Clear Liquid

06

What researchers measure

Primary outcomes

  1. Preoperative anxiety measured by Modified Yale Preoperative Anxiety Scale (m-YPAS)

    Evaluation of preoperative anxiety and agitation in pediatric surgical patients receiving maltodextrin-containing clear liquids compared with control patients receiving non-sugared clear liquids before elective surgery.

    Time frame: 20 to 30 minutes before surgery

Secondary outcomes

  1. Postoperative pain assessed by Visual Analogue Scale (VAS)

    Evaluation of postoperative pain using the Visual Analogue Scale (VAS) in pediatric patients after elective surgery.

    Time frame: 2 hours after surgery

  2. Eligibility for discharge after surgery

    Evaluation of the proportion of pediatric patients considered eligible for discharge 6 hours after elective surgery according to postoperative recovery and clinical conditions.

    Time frame: 6 hours after surgery

  3. Evaluation of postoperative vomiting

    Incidence of participants experiencing at least one episode of postoperative vomiting during the first 6 hours after surgery.

    Time frame: Within 6 hours after surgery

  4. Preoperative oxidative stress

    Blood chemistry tests for the assessment of preoperative stress

    Time frame: Immediately before surgery

  5. Preoperative stress assessed by State-Trait Anxiety Inventory - Form Y (STAI-Y)

    Evaluation of preoperative stress using the State-Trait Anxiety Inventory - Form Y) in parents of pediatric patients before elective surgery

    Time frame: Immediate preoperative period

  6. Evaluation of postoperative oral feeding tolerance

    Oral feeding tolerance will be assessed by the ability to tolerate the first oral intake without vomiting or need to interrupt feeding.

    Time frame: Within 6 hours after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for May 2027, 20 months after the start.

Of 144 non-industry interventional studies with no phase under Fasting, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 40. This study's planned 20 months is close to that.

Counting every sponsor, half of 149 studies reached it within 18 months; a quarter within 6 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 6, 2026
StartActual
Sep 3, 2025
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07686029
Lead sponsor
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Sep 3, 2025
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Clinical Trial Center
Contact
clinicaltrialcenter@ospedale.al.it
0131206893

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maltodextrin

Start the discussion